Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : 4'-Galactooligosaccharide
Therapeutic Area : Endocrinology
Study Phase : Undisclosed
Recipient : University of Aberdeen
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of a Sugar Replacement on Blood Glucose Levels in Healthy Adults
Details : Galactooligosaccharide is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Hyperglycemia.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
December 03, 2024
Lead Product(s) : 4'-Galactooligosaccharide
Therapeutic Area : Endocrinology
Highest Development Status : Undisclosed
Recipient : University of Aberdeen
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fermented Milk
Therapeutic Area : Gastroenterology
Study Phase : Undisclosed
Recipient : University of Guadalajara
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Fermented Milk is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Constipation.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
May 29, 2024
Lead Product(s) : Fermented Milk
Therapeutic Area : Gastroenterology
Highest Development Status : Undisclosed
Recipient : University of Guadalajara
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lactobacillus Casei Strain Shirota Fermented Milk
Therapeutic Area : Gastroenterology
Study Phase : Undisclosed
Sponsor : Bach Mai Hospital | Vietnam National University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lactobacillus Casei Strain Shirota Fermented Milk for Alleviating Hard Stools in Vietnam
Details : Lactobacillus Casei Strain Shirota Fermented Milk is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Constipation.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
August 09, 2023
Lead Product(s) : Lactobacillus Casei Strain Shirota Fermented Milk
Therapeutic Area : Gastroenterology
Highest Development Status : Undisclosed
Sponsor : Bach Mai Hospital | Vietnam National University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Yakult
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Recipient : Endang Sutriswati Rahayu
Deal Size : Inapplicable
Deal Type : Inapplicable
Effects of Yakult Ingestion in Residents and Staffs at Indonesian Elderly Houses
Details : Yakult is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
April 04, 2022
Lead Product(s) : Yakult
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Recipient : Endang Sutriswati Rahayu
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Yakult
Therapeutic Area : Musculoskeletal
Study Phase : Undisclosed
Recipient : Taipei Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Fermented Milk Containing Lactobacillus Casei Strain Shirota in Sarcopenia Elderly
Details : Yakult is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Sarcopenia.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
August 02, 2021
Lead Product(s) : Yakult
Therapeutic Area : Musculoskeletal
Highest Development Status : Undisclosed
Recipient : Taipei Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Yakult
Therapeutic Area : Endocrinology
Study Phase : Undisclosed
Recipient : Loughborough University
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Yakult Ingestion on Diet-induced Insulin Resistance in Humans
Details : Yakult is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Insulin Resistance.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
January 31, 2017
Lead Product(s) : Yakult
Therapeutic Area : Endocrinology
Highest Development Status : Undisclosed
Recipient : Loughborough University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Probiotic
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Japan Aerospace Exploration Agency
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : This is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
December 01, 2015
Lead Product(s) : Probiotic
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Japan Aerospace Exploration Agency
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Resminostat
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Resminostat is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Hepatocellular.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 27, 2015
Lead Product(s) : Resminostat
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TAS-118
Therapeutic Area : Oncology
Study Phase : Phase III
Recipient : Taiho Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TAS-118 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Stomach Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 23, 2014
Lead Product(s) : TAS-118
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Taiho Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fermented Milk
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : University of São Paulo General Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Once a Day Use of Lactobacillus Casei Shirota on HIV-infected Patients Infected Patients
Details : Fermented Milk is a Dietary Supplement drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of HIV Infections.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
May 23, 2014
Lead Product(s) : Fermented Milk
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : University of São Paulo General Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
